[ad_1]
Kuala Lumpur, Malaysia
Malaysia on Tuesday granted conditional approval for the use of coronavirus vaccines produced by British company AstraZeneca and China’s Sinovac.
The director general of the Ministry of Health, Noor Hisham Abdullah, said full approval of the vaccines would be granted if companies provide additional information on their effectiveness and safety.
The country launched a vaccination campaign last month using the vaccine developed by Pfizer-BioNTech.
Abdullah noted that the Russian Sputnik V vaccine is also under review for approval.
As part of its national COVID-19 vaccination program, Malaysia launched vaccinations on February 24 and continues to vaccinate health workers and security forces.
In phase two, from April to August, 9.4 million people will be vaccinated, including those over 60, chronic patients and people with disabilities.
In phase three, the coronavirus vaccine will be administered to 13.7 million people over the age of 18 between May 2021 and February 2022.
Malaysia has reached an agreement to obtain a total of 66.7 million doses of vaccines from Pfizer-BioNTech, AstraZeneca, Sinovac, CanSinoBIO and Sputnik V, with the aim of creating 70% immunity in the country.
With the start of mass vaccinations, 126,000 people are expected to be vaccinated daily in 600 vaccination centers across the country.
Malaysia has so far reported over 304,000 infections and 1,141 deaths with nearly 279,000 recoveries.
The Anadolu Agency website contains only a portion of the stories offered to subscribers in the AA News Broadcasting System (HAS), and in summary form. Please contact us for subscription options.
[ad_2]
Source link
